Press Release: European Medicines Agency publishes first summary of a risk-management plan for a medicine

The European Medicines Agency published in March 2014 the first summary for the public of the risk-management plan (RMP) of a newly authorised medicine. This RMP summary, which concerns the medicine Neuraceq, describes what is known and not known about the medicine’s safety and states what measures will be taken to prevent or minimise its risks.